Brief: Newron Receives FDA Rare Pediatric Disease Designation For Sarizotan
19/11/2019 12:26
Nov 19 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* NEWRON RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR
SARIZOTAN FOR THE TREATMENT OF RETT SYNDROME
Source text for Eikon: ID:nBwbMtDvKa
Further company coverage: NWRN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study